![David Thurston](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Thurston
Fondateur chez Pheon Therapeutics Ltd.
Postes actifs de David Thurston
Sociétés | Poste | Début | Fin |
---|---|---|---|
Transcriptogen Ltd.
![]() Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Directeur/Membre du Conseil | 25/03/2013 | - |
Directeur Technique/Scientifique/R&D | 25/03/2013 | - | |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Directeur Technique/Scientifique/R&D | 01/01/2005 | - |
Fondateur | 01/01/2005 | - |
Historique de carrière de David Thurston
Anciens postes connus de David Thurston
Sociétés | Poste | Début | Fin |
---|---|---|---|
ADC Products (UK) Ltd.
![]() ADC Products (UK) Ltd. Medical/Nursing ServicesHealth Services ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom. | Directeur/Membre du Conseil | 01/08/2000 | 29/02/2012 |
Directeur Technique/Scientifique/R&D | 01/08/2000 | 29/02/2012 | |
Fondateur | 04/02/2010 | 29/02/2012 |
Statistiques
Internationale
Royaume-Uni | 4 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
Director/Board Member | 2 |
Founder | 2 |
Sectorielle
Health Technology | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
ADC Products (UK) Ltd.
![]() ADC Products (UK) Ltd. Medical/Nursing ServicesHealth Services ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom. | Health Services |
Transcriptogen Ltd.
![]() Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Health Technology |
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
- Bourse
- Insiders
- David Thurston
- Expérience